Replies to post #57839 on Biotech Values

[tony111]

Xrymd,

I have pubmeded Bovine thrombin+coagulopathy and many articles come out. If ZGEN sales rep can show this journal articles to doctors, I think it will be a strong case. I agree its not a significant problem because the rate of coagulopathy is so low, but how is paying 14 bucks more going to hurt the profit for the hospital? I am sure if KG aggresively cuts its price for multi year contracts, ZGEN will do the same too.

Here is some ref:
http://www.ncbi.nlm.nih.gov/pubmed/15734434?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

http://www.ncbi.nlm.nih.gov/pubmed/15354638?ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

http://www.ncbi.nlm.nih.gov/pubmed/12811284?ordinalpos=9&itool=En
trezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

http://www.ncbi.nlm.nih.gov/pubmed/11854743?ordinalpos=14&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum